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Abstract Human metapneumovirus (hMPV) epidemics
vary in time and severity. We report findings for PCR for
hMPV and respiratory syncytial virus (RSV) performed on
nasopharyngeal aspirates (NPA) of hospitalized and outpa-
tient children with respiratory tract infections between
October 2004 and April 2008. A total of 3,934 NPAs were
tested for hMPV and 3,859 for RSV. Of these, 198 (5%)
were hMPV positive and 869 (23%) were RSV-positive.
Median age was 17 months and 9 months for hMPV and
RSV, respectively. Fifty-nine percent of hMPV and 58% of
RSV patients were hospitalized. Proportions of hMPV
positive samples for the four winter seasons were 0.4%,
11%, 0.2%, and 14%. For RSV, they were 28%, 15%, 28%,
and 28%. HMPV epidemics follow a biannual variation in
our area. Major epidemics were observed in winter seasons
starting in odd years (2005/06 and 2007/08), minor
epidemics in those starting in even years (2004/05 and
2006/07). RSV epidemics usually follow a reciprocal
biannual pattern, leading to annually alternating major
RSV and hMPV epidemics.
Keywords Humanmetapneumovirus . Respiratory syncytial
virus . Biannual . Children . Epidemic
Introduction
Human metapneumovirus (hMPV), a paramyxovirus first
discovered in the Netherlands in 2001 [29], causes acute
respiratory tract infections (RTI) in children and adults
worldwide [2, 4, 8, 9, 13–17, 20–24, 26–28, 33].
Since October 2004, nasopharyngeal aspirates (NPA)
from in- and out-patients with RTI have been tested for
hMPV by a reverse-transcriptase-polymerase chain reaction
(RT-PCR) as part of a broad panel of multiplex-PCR in our
laboratory [19], and clinical characteristics of patients have
been obtained [3]. Our initial observations revealed that
only a few nasopharyngeal samples tested positive for
hMPV in the first winter season, followed by an epidemic
in the next winter season. In the meantime, epidemiological
observations in Austria, Germany and Sweden have
suggested that hMPV activity appears to follow a biannual
cycle [1, 25, 31] similar to previous findings with
respiratory syncytial virus (RSV) in Europe [10, 11]. Here,
we present the results from our continuous ongoing
surveillance and provide further evidence that hMPV
causes biannual major epidemics.
Materials and methods
Study subjects
Procedures were similar as in previous studies by our group
[3, 19]. Specifically, nasopharyngeal aspirates (NPA) were
obtained from patients hospitalized with RTI on a routine
basis. Further, NPA were collected from ambulatory
patients with RTI presenting to the emergency room of
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our children’s hospital or to pediatricians in private
practices in close vicinity.
Clinical characteristics (age, gender, prematurity, under-
lying chronic diseases, onset of symptoms, duration of
illness, clinical signs and symptoms, medication, and final
clinical diagnosis information) in hospitalized patients with
hMPV infections were abstracted from their medical
records. Informed consent was not deemed necessary by
the ethics committee for this procedure. In ambulatory
patients, the same data was obtained by use of standardized
questionnaires sent to the treating physicians and informed
consent was obtained from the patients’ parents. All
patients with respiratory tract infection and a nasopharyn-
geal specimen obtained for virus detection were included.
Patients without parental agreement for study participation
were excluded from analyses.
Laboratory investigations
Details have been described before [3]. Briefly, from October
2004 onwards, RT-PCR for hMPV was performed by use of a
one-tube reaction (Titan One Tube RT-PCR System, Roche
Diagnostics GmbH Mannheim, Germany) and a primer pair
comprising hMPV L-L Hex-labeled (5′ CAT GCC CAC TAT
AAA AGG TCA G 3′) and hMPV L-R1 (5′ CAC CCC AGT
CTT TCT TGA AA 3′), amplifying a fragment of 170 bp in
the polymerase gene as described by van den Hoogen et al.
[30]. In addition, a second primer pair hMPV N-L1 (5′ GCA
TGC TAT ATT AAA AGA GTC TCA 3′) and hMPV N-R
FAM-labeled (5′ ATC TCA GCA GCATAT TTG TA 3′) was
used for amplification of a highly conserved fragment of
157 bp in the nucleoprotein gene. These primers were slightly
modified based on those previously described by Maertzdorf
et al. [18]. The two hMPV RT-PCRs were integrated in the
existing in-house RT-multiplex-PCR as follows: primers for
hMPV N gene were combined with those for RSV, influenza
viruses A and B (block 1) and primers for HMPV L gene
were combined with those for adenoviruses and parainfluenza
type 1 and type 3 viruses (block 2).
After careful internal validation, PCR technique was
changed to a one-step RT-PCR with TaqMan (Applied
Biosystems 7500 Real Time PCR System) in October 2007
according to the manufacturer’s instructions (TaqMan One-
Step RT-PCR Master Mix Reagents, Applied Biosystems,
Roche, Branchburg, New Jersey, USA). This RT-PCR
amplifies the hMPV NL-N gene by use of a primer pair
comprising 5′-CATATAAGCATGCTATTAAAAGAGTCT
C-3′ and 5′-CCTATTTCTGCAGCATATTTGTAATCA
G-3′ specific to all hMPV subtypes, and a 5′-FA
M-TGYAATGA TGAGGGTGTCACTGCGGTTG-TAMR
A-3′ primer. Until December 2007, hMPV L-Gen was
amplified as before but disregarded thereafter due to its
suboptimal sensitivity [3, 7].
Statistical methods
Data were entered into a database and statistical analyses
were performed using SPSS (version 13.0, SPSS, Inc.,
Chicago, IL, USA). Clinical characteristics and laboratory
variables were compared by Student’s t-test, Mann–
Whitney U test, Fisher’s exact test, chi-squared test, or
odds ratio analysis as appropriate. A two-sided P value of
<0.05 was considered significant.
The study protocol was approved by the University of
Basel Ethics Committee.
Results
Epidemiological characteristics
Findings from the first study period, comprising 2,582 NPA
received between October, 11, 2004 and February 28, 2006,
have been published before [3]. Here, we present results for
the extended period until May 31, 2008 from a total of
5,057 NPA. Based on the physicians’ orders for detection
of viruses from multiplex-PCR blocks 1 and 2, 3,934
(77.8%) NPA were tested for hMPV and 198 (5.0%)
specimens were positive. For RSV, 3,859 NPA were tested
and 869 (22.5%) were positive.
Only 20 (0.2%) of 1,003 NPA obtained during the three
warm study seasons (April to September) were positive for
hMPV. Similarly, three of 691 (0.4%) and two (0.2%) of
897 NPA tested for hMPV in the winter seasons October
2004 to March 2005 and October 2006 to March 2007,
respectively, were positive for hMPV. In contrast, major
hMPV epidemics occurred during the alternating winter
seasons 2005/2006 and 2007/2008 with 64 (11.4%) of 560
and 109 (13.9%) of 783 NPA positive (Fig. 1). During the
peaks of the epidemics, up to 30% of all RTI were caused
by hMPV (Fig. 2).
In comparison, major RSV epidemics occurred early
during the winter seasons 2004/2005 and 2006/2007 (i.e.,
in alternating years compared to hMPV epidemics) and one
minor and one major RSV epidemic occurred late during
the winter seasons 2005/2006 and 2007/2008, respectively
(Figs. 1 and 2).
Seventeen (8.6%) of 198 hMPV-infected patients were
documented to be coinfected with other respiratory patho-
gens: 11 with RSV, four with M. pneumoniae, and two with
adenovirus.
Clinical characteristics
Informed consent could be obtained from the parents of all
ambulatory children infected with hMPV during the second
study period. Basic characteristics of patients were remark-
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ably similar compared to the first period with mean age of
32 (first period) and 32 months (second period) and median
age of 15 (first period) and 17 months (second period),
respectively. In comparison, RSV-positive patients had a
mean age of 16 and 16 months and median age of 9 and
8 months, respectively.
Overall, more males than females had hMPV and RSV
infections (both 59%).
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Fig. 2 Proportion of hMPV and
RSV detected by PCR in naso-
pharyngeal aspirates from
patients with respiratory tract
infections
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Fig. 1 Seasonal distribution of
hMPV and RSV detected by
PCR in nasopharyngeal aspi-
rates from patients with respira-
tory tract infections
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The following comparative analyses of clinical charac-
teristics comprise 111 hMPVand 558 RSV-positive patients
during the second study period without co-infections. Of
patients with hMPV infection, 48 (43%) were infants
including one (0.9%) newborn (<1 month of age) compared
to 343 (61%; OR 0.48, 95% confidence interval 0.31–0.74,
p<0.001) infants and 35 (6.3%; OR 0.15, 95% CI 0.01-
0.92; p=0.03) newborns among RSV-positive patients.
Hospitalization rates were 59% (n=65) for hMPV and
58% (n=326) for RSV infections; intensive care treatment
was required due to imminent respiratory failure in five
(4.5%) and 39 (7.0%; p=0.33) patients with hMPV and
RSV infections, respectively.
A summary of clinical characteristics of hMPV infections
and a comparison between hospitalized children and out-
patients are demonstrated in Table 1. Dyspnea, diarrhea,
pneumonia, feeding difficulties, and use of corticosteroids
were more frequently among hospitalized children who also
tended to be younger than out-patients (31.4±45.8 months
versus 33.9±32.9 months, p=0.06). The majority of patients
had LRTI (73%; out-patients: 70%, in-patients: 75%).
Further, mean duration of hospitalization was 4.2±3.2 days
(median 3 days, range 1–20 days) and thus shorter than
during the first study period (mean 6.6±8.9 days; median 4).
The difference in age distribution between hospitalized
patients (median 25 months; range 3–148) and out-patients
(15 months; 1–207) was not significant (p=0.06).
Thirty-two (29%) of 111 hMPV-infected children had
some form of underlying chronic disease. Eighteen (56%)
of them were hospitalized compared with 47 (59%) of 79
primary healthy children (p=0.75).
Signs and symptoms of hMPV infection were not
different whether the disease occurred during the warm
(April to September) or cold (October to March) study
seasons (data not shown).
Discussion
Human metapneumovirus is a member of the Paramyx-
oviridiae family and was first isolated from young children
with RTI [29]. We report findings from our extended
ongoing surveillance of hMPV, which comprises 198 cases
and is one of the most comprehensive case series so far.
In the first two study years, we had observed only few
hMPV infections in the winter of 2004/2005 whereas a
Variables Total Out-patients In-patients p value Odds ratioa
N/known (%) N/known (%) N/known (%) (95% CI)
Male gender 62/111 (56) 30/46 (65) 32/65 (49) 0.096 0.5 (0.2–1.2)
Prematurity (<37 weeks) 23/108 (21) 8/46 (17) 15/62 (24) 0.393 1.5 (0.5–4.4)
Body temperature
38.5–38.9°C 22/107 (22) 9/42 (21) 13/65 (20) 0.858 0.9 (0.3–2.7)
≥39°C 55/107 (52) 17/42 (40) 38/65 (58) 0.069 2.1 (0.9–4.9)
Cough 107/111 (96) 46/46 (100) 61/65 (94) – –
Dyspnea 50/111 (45) 10/46 (22) 40/65 (62) ≤0.001 9.6 (3.5–27)
Rash 10/109 (9) 4/46 (9) 6/63 (10) 0.882 1.1 (0.3–4.2)
Oral fluid intolerance 54/106 (51)b 12/46 (26) 42/60 (70) ≤0.001 6.6 (2.8–15.6)
Vomiting 33/107 (31)c 11/46 (24) 22/61 (36) 0.178 1.8 (0.8–4.2)
Diarrhea 23/107 (21)c 4/46 (9) 19/61 (31) 0.005 4.7 (1.5–15.1)
URTI 95/111 (85) 40/46 (87) 55/65 (85) 0.729 0.8 (0.3–2.5)
Conjunctivitis 10/111 (9) 2/46 (4) 8/65 (12) 0.149 3.1 (0.6–15.3)
Rhinitis 93/111 (84) 40/46 (87) 53/65 (82) 0.446 0.7 (0.2–1.9)
Pharyngitis 55/111 (50) 17/46 (37) 38/65 (58) 0.026 2.4 (1.1–5.2)
Acute otitis media 19/109 (17) 8/46 (17) 11/63 (17) 0.993 4.7 (0.4–2.7)
LRTI 81/111 (73) 32/46 (70) 49/65 (75) 0.496 1.3 (0.6–3.1)
Pneumonia 33/111 (30) 5/46 (11) 28/65 (43) ≤0.001 6.2 (2.2–17.7)
Bronchitis 59/111 (53) 28/46 (61) 31/65 (48) 0.171 0.6 (0.3–1.3)
Bronchiolitis 7/111 (6) 4/46 (9) 3/65 (5) 0.384 0.5 (0.1–2.4)
Treatment
Antibiotics 38/111 (34) 15/46 (33) 23/65 (35) 0.762 1.1 (0.5–2.7)
Corticosteroids 19/111 (17) 3/46 (6) 16/65 (25) 0.004 4.7 (1.2–22)
Inhaled broncho-dilators 44/111 (40) 16/46 (35) 28/65 (43) 0.379 1.4 (0.6–3.3)
Oxygen supplementation 37/111 (33) 0/46 (0) 37/65 (57) 0.001 –
Table 1 Clinical characteristics
in 46 out-patients and 65 hospi-
talized patients with hMPV
infections
a Odds ratios were calculated
where meaningful
b Five patients excluded because
of concomitant rotavirus infec-
tion (n=4) and oral tube feeding
(n=1)
c Four patients excluded because
of concomitant rotavirus infection
1458 Eur J Pediatr (2009) 168:1455–1460
major epidemic of hMPV infections occurred in the
following winter. At that time, we had speculated that this
observation could represent a pattern of biannual major
epidemics similar to those observed with RSV [3].
Continued surveillance now supports the assumption of a
biannual pattern and in the meantime three other groups
came to the same conclusion [1, 25, 31]. In a retrospective
RT-PCR-based study from Sweden, hMPV was found in
143 of 4,989 specimens from patients of all ages with
respiratory tract infection [25]. The proportion of positive
samples (2.9%) was similar to our findings (5.0%), where
the higher proportion in our study probably reflects the fact
that it was restricted to children. In accordance, in the
respiratory pathogen surveillance in children in Germany,
with more than 12,000 specimens between 2002 and 2006,
hMPV was also recovered in 5.0% [31]. In addition, the
selection of PCR primers may have played a role. In the
Swedish study, only L gene primers were used which have
been shown to be less sensitive than N gene primers [7].
Further, in a single-center study over a 7 year period from
Vienna, Austria, 109 (6.8%) of 1,612 NPA specimens in
children under 2 years of age were positive for hMPV [1].
Interestingly, the biannual hMPV epidemics in Sweden
occur in even years (e.g., 2004/2005) [25] whereas in
Switzerland (our study), Germany [31], and (based on a
2 year surveillance) possibly also in Italy [6], they occur in
odd years (e.g., 2005/2006). However, in all of these
countries hMPV epidemics are anti-cyclical to RSV epidem-
ics. No plausible explanations have been offered for these
peculiar epidemiological findings. In the study from Austria,
the biannual pattern refers to the peaks of hMPV activities
which alternate between spring and winter whereas the
proportions of positive hMPV specimens by no means were
as different from year to year as in our study [1].
Our original clinical observations on the first 74 patients [3]
have now been substantiated with a total cohort of almost 200
patients with documented clinical course of hMPV infection.
In summary, signs and symptoms of hMPV infection are
similar to those of RSV infection although patients with
hMPV infections are significantly older than RSV infected
patients. The clinical presentation of both hospitalized and
out-patients with hMPV respiratory tract infection comprise
cough, rhinitis, and dyspnea as the major findings.
Approximately 50% of patients were treated with anti-
biotics for suspected bacterial infection during their illness
in the first study phase and this percentage was reduced to
34% in the second phase. Further, duration of stay in
hospitalized patients decreased from a mean of 6.6 days to
4.2 days. These changes reflect the current trend towards a
preference for ambulatory care and a more stringent use of
antibiotics, respectively.
Proportions of hMPV-infected patients with chronic
underlying diseases (30% versus 29%) and a history of
prematurity (11% versus 21%) were comparable in both
study phases and also similar to previous observations [5,
12, 30, 32]. These rates are high compared to the normal
population and either indicate an increased susceptibility
for infection or a bias towards a greater likelihood for
diagnostic tests in these high-risk patients.
In conclusion, hMPV infections lead to upper and lower
respiratory tract disease in primary healthy children but also in
patients with underlying disease. The clinical course is usually
uncomplicated and the observed seasonality with biannual
early winter epidemics, anti-cyclical to those caused by RSV,
allows assumptions on the expected burden for the health care
system in the ambulatory and clinical setting year by year.
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